Tocilizumab and sarilumab are classified as humanized monoclonal antibodies against the interleukin-6 receptor and are used in rheumatology.
CADTH has conducted a Technology Review on tocilizumab and sarilumab for their potential use in managing COVID-19.
Link to Report
Tocilizumab and Sarilumab: Evidence Review and Appraisal (updated February 25, 2021)
Was this site helpful?
If you couldn’t find what you are looking for, please submit a request.